Good news for lymphoma patients! CAR-T Cell Therapy Product Second Line Indications Approved for Market in Lymphoma | Cells | CAR

Release time:Apr 13, 2024 23:45 PM

The reporter learned from Fosun Pharmaceuticals today that its joint venture company, Fosun Kate, has developed Aquilense Injection for the treatment of adult B-cell lymphoma that is ineffective in first-line immunochemotherapy or relapses within 12 months after first-line immunochemotherapy. The registration application has been conditionally approved by the National Medical Products Administration, marking the launch of this CAR-T cell therapy product as a second-line indication.

Adult large B-cell lymphoma is a common malignant lymphoma, accounting for 30% -40% of non Hodgkin's lymphoma. It has the characteristics of few treatment plans, rapid disease progress, high mortality, and short survival period. In recent years, the incidence of incidence rate in China has shown a rapid growth trend. In June 2021, Aquilense Injection became the first CAR-T cell therapy product approved for sale in China, used to treat adult patients with recurrent or refractory large B-cell lymphoma who have previously received second-line or above systemic treatment.

As of now, this personalized and one-time treatment cell drug has benefited over 500 patients with relapsed/refractory large B-cell lymphoma, bringing technological breakthroughs to cancer treatment in China.

Fosun Kate researchers are conducting CAR-T cell analysis research.

Fosun Medical experts introduce that CAR-T therapy is an individualized treatment method that utilizes the human body's own immune system. Technicians extract T cells from patients through white blood cell isolation and modify them with chimeric antigen receptors, allowing T cells to recognize specific antigens on cancer cells and respond accordingly. After completing the genetic engineering modification, technicians transfused CAR-T cells back to the same patient.


Good news for lymphoma patients! CAR-T Cell Therapy Product Second Line Indications Approved for Market in Lymphoma | Cells | CAR

This month, the annual meeting of the American Society of Clinical Oncology and the New England Journal of Medicine presented the main overall survival analysis results of a global multicenter phase III randomized controlled study in both oral and full-text formats. At a median follow-up time of 47.2 months, compared to second-line standard treatment, Agilensei significantly improved patient OS and reduced the risk of mortality by 27.4%.

According to the introduction, 57% of patients in the SOC group received cell therapy on or after the third line after leaving the group. In this situation, the median OS of the SOC group has significantly increased, but the statistical difference in OS between the two groups still achieved positive results, which is encouraging.

Previously, there were no CAR-T cell therapy products available in China for the treatment of adult large B-cell lymphoma that was ineffective in first-line immunochemotherapy or relapsed within 12 months after first-line immunochemotherapy. The approval and launch of the new second-line indications for Yikaida has achieved new progress in the treatment of adult large B-cell lymphoma, bringing hope to patients who have failed or relapsed first-line immunochemotherapy.

Shanghai International Sister City Youth "Play" Summer Camp Experience Traditional Culture, Make Pankou, Learn Paper Cuttings, Make Dumplings International | Youth | Make Dumplings
Shanghai International Sister City Youth "Play" Summer Camp Experience Traditional Culture, Make Pankou, Learn Paper Cuttings, Make Dumplings International | Youth | Make Dumplings

Making coils, learning Paper Cuttings, making dumplings, walking into the home of summer camp volunteers and feeling the life of Shanghai people... On the 20th, the 2023 Shanghai International Sister City Youth Summer Camp officially opened in Shanghai Shidong Experimental School. 73 campers from 13 cities in 12 countries gathered in Shanghai to open the annual international sister city youth exchange event with their peers in Shanghai. The young partners together carried out activities such as learning excellent traditional Chinese culture courses such as Chinese and traditional Chinese painting, intangible cultural heritage, Chinese clothing, disco, Paper Cuttings, seal cutting, calligraphy, pottery, tea art, Yanzhi, dragon dance, youth forum exchanges in sister cities, investigation of urban cultural landscape, visits to universities and venues, city orientation challenges, and local family life experiences, etc., to bloom their youth. In addition to a rich and colorful summer camp physical activity experience, campers and volunteers

Undergraduate voluntary application starts today! These important reminders and suggestions must be read, @ College Entrance Examination Stage | Undergraduate | Volunteer
Undergraduate voluntary application starts today! These important reminders and suggestions must be read, @ College Entrance Examination Stage | Undergraduate | Volunteer

@All college entrance examination candidates, according to the schedule of the college entrance examination, will fill in their undergraduate preferences for all batches except for the comprehensive evaluation batch from 8:00 a.m. to 8:00 p.m. daily from July 1st to 2nd, and from 8:00 a.m. to 12:00 a.m. on July 3rd. The specific contents of this voluntary application include zero voluntary batch, advance batch, art and sports class A batch, local rural special plan batch, special type enrollment, and ordinary batch. The filling method is as follows: Fresh high school graduates in this city will be arranged uniformly by the high school where they are enrolled; Non local fresh high school graduates will be arranged uniformly by the district recruitment office where they apply. It is important to remind candidates that during the voluntary application period from July 1st to 3rd, as the admission of the comprehensive evaluation batch has not yet been completed, candidates who have filled out the comprehensive evaluation batch of voluntary applications still need to carefully fill out other batches of undergraduate voluntary applications

Investment+Services Drive Anti Cancer Drugs into Clinical Practice | Entrepreneurial Stories in Incubators, Second Entrepreneurial Biology for CEOs of Listed Companies | Incubators | Clinical | Incubators
Investment+Services Drive Anti Cancer Drugs into Clinical Practice | Entrepreneurial Stories in Incubators, Second Entrepreneurial Biology for CEOs of Listed Companies | Incubators | Clinical | Incubators

Recently, with the approval of the National Medical Products Administration, the Class 1 innovative drug CC312 developed by Huihe Biotechnology has initiated phase I clinical trials for the treatment of recurrent/refractory CD19 positive B-cell malignant hematological tumors. This is the first domestically and the third globally approved triple specific antibody drug based on CD28 co stimulatory signals to enter clinical practice. When it comes to the development history of this new triple antibody drug, Dr. Zhu Huaxing, the founder of Huihe Biotechnology, still remembers vividly: "Before 2019, there was no triple antibody drug approved for clinical use globally, and some investors couldn't understand CC312. During a critical period of company development, Nokai Xinkang Fund invested 30 million yuan to help us complete Series A financing." Nokai Xinkang is a venture capital fund initiated by Xinze Entrepreneurship Incubator. This incubation company, which has been deeply cultivated in Zhangjiang Science City for many years

"Zidong Taichu" Full Modal Large Model Released, Precisely Positioned 3D Scene, Listening to "Moonlight Song" and Talking about Beethoven Images | Applications | Beethoven
"Zidong Taichu" Full Modal Large Model Released, Precisely Positioned 3D Scene, Listening to "Moonlight Song" and Talking about Beethoven Images | Applications | Beethoven

Not only can you hear Beethoven talk freely in "Moonlight", but you can also achieve precise positioning in three-dimensional scenes, and complete scene analysis through the combination of images and sound. On June 16, at the AI Framework Ecological Summit, the Institute of Automation of the Chinese Academy of Sciences officially released the full mode large model of "Zidong Taichu". This model is the 2.0 version upgraded from the 1.0 version of the 100 billion parameter multimodal model "Zidong Taichu". On the basis of voice, image and text three modes, it adds video, sensor signal, 3D point cloud and other modal data, breaks through the key technologies such as multimodal correlation for cognitive enhancement, and has full modal understanding, generation and correlation capabilities. At the meeting, Xu Bo, the director of the Institute of Automation, presented for the first time in real time the "Zidong Taichu" full modal cognitive model in music understanding

Perseverance is a life experience. Lingling Middle School has weak muscles. Candidates complete the college entrance examination: no matter what difficulties they experience. High school | school | college entrance examination
Perseverance is a life experience. Lingling Middle School has weak muscles. Candidates complete the college entrance examination: no matter what difficulties they experience. High school | school | college entrance examination

"The college entrance examination is an experience in our lives. Looking back on the preparation for the entire senior year of high school, we cannot help but marvel at the preciousness of time. No matter what difficulties we have gone through, I believe that as long as we persist, it will become my lifelong wealth. Today, after completing the morning foreign language listening and speaking test of the college entrance examination, Xiao Song, a senior student of Lingling High School, came out of the examination center of East China University of Science and Technology Affiliated Middle School. The senior year graduate sitting in a wheelchair said," Although academic and life are not small tests for me, I have faced many difficulties in adversity and have never given up on my dream of taking the college entrance examination. "Xiao Song suffered from congenital muscular dystrophy since childhood and entered Lingling High School in high school." Later, the school provided him with classrooms on low floors and close to the toilet, making it easier for him to enter and exit, allowing him to face his academic life with more confidence. At school, I met many kind and enthusiastic people